NP5.DE

Newron Pharmaceuticals SpA [NP5.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NP5.DE Stock Summary

Top 10 Correlated ETFs

NP5.DE

Top 10 Correlated Stocks

NP5.DE

In the News

NP5.DE Financial details

Company Rating
-
Market Cap
147.19M
Income
-34.22M
Revenue
15.36M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
19 Sep 2024
P/E
-8.42
Forward P/E
-
PEG
-0.88
P/S
24.16
P/B
-10.49
P/C
-
P/FCF
-13.25
Quick Ratio
4.52
Current Ratio
5.65
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.92
EPS next Y
-
EPS next Q
-
EPS this Y
-3.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.41%
Revenue last 5Y
6.11%
Revenue Q/Q
-33.76%
EPS Q/Q
38.46%
-
-
-
-
SMA20
-12.5%
SMA50
-
SMA100
-30%
Inst Own
-
Inst Trans
-
ROA
-47%
ROE
320%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-218%
Profit Margin
-287%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.82-12.0
52W High
-40.33%
52W Low
+138.67%
RSI
37
Rel Volume
0.29
Avg Volume
10.08K
Volume
2.96K
Perf Week
-4.66%
Perf Month
-14.35%
Perf Quarter
-21.92%
Perf Half Y
-23.91%
-
-
-
-
Beta
0.703
-
-
Volatility
0.04%, 0.36%
Prev Close
-1.65%
Price
7.16
Change
0.7%

Something similar

Top by Market Cap
MIX.JO
APC.DE
FB2A.DE
CMC.DE
LLY.SW
Top Correlated ETFs
CEMQ.DE
EUPE.DE
CAPE.PA
ECOF.MI
ZEQ.TO
Top Correlated Stocks
ALAGR.PA
VVY.AS
AMEQ.DE
BRNL.NS
JBMA.NS
Similar Market Cap
ASPO.HE
FRI
0368.HK
JIG
FDEV.L

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 10.08K
  • Market Capitalization 147.19M
  • Employee 22
  • CEO Mr. Stefan Weber
  • Headquarters Bresso,MILANO,IT
  • IPO Date 2019-07-04
  • Website https://www.newron.com/

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.